EU Rejects two MS Medications from reaching the European Market
January 21, 2011 Both, Biogen-Acorda’s Fampyra, click here to review related stories and Merck’s MS Oral Pill, click here for available…
The first pill for multiple sclerosis (MS) could be available in the UK within a “few months”.
Jan 21, 2011 European experts have recommended that regulators give the green light to Gilenya, paving the way to an EU-wide…
Stuart Schlossman
Beyond the Immune System?
Beyond the Immune System? Gilenya is the first oral MS drug available and it was approved to treat relapsing forms…
Stuart Schlossman
With the Recent Launch of Novartis’s Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment
EXTON, Pa., Dec. 13, 2010 /PRNewswire/ — BioTrends Research Group, Inc. finds that with the introduction of Novartis’ Gilenya, the first oral disease-modifying…
Stuart Schlossman
Teva multiple sclerosis pill shines in big study
Thu Dec 9, 2010 1:27pm GMT * Teva hopes for U.S. regulatory green light in 2 years * Teva developing…
Stuart Schlossman
Multiple Sclerosis Study Uncovers Early Impact Of Gilenya
TreatmentTrends®, Multiple Sclerosis Study Uncovers Early Impact Of Gilenya On Perceptions And Anticipated Use Of Products Within The MS Market…
Stuart Schlossman
Gilenya Launch for Multiple Sclerosis Starts Slow for Novartis
November 11, 2010 Analyses are solely the work of the authors and have not been edited or endorsed by GLG.…
Stuart Schlossman
The recent approval in the US of Novartis’ orally administered Gilenya (fingolimod) heralds a new phase in the treatment of Multiple Sclerosis (MS)
MS Drug Therapies – “What the Future Holds” Over the last few years, the MS market has been driven by…
Stuart Schlossman
A comprehensive overview of the eight FDA-approved disease-modifying therapies used to slow MS activity (including the newly approved oral therapy, Gilenya), and initial findings on many of the experimental treatments in development for the treatment of MS
Information provided by: Cherie C. Binns RN BS MSCN From the MS Association of America’s Motivator Summer/Fall 2010 issue Based on…
Stuart Schlossman
Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
October 26, 2010 TERACLES is the First Phase III Study of an Oral Drug as an Add-On to Standard Therapy…
Stuart Schlossman
